Showing results (491-500 of 1,600) with videos related to
Sort By:
Pageof 160
JAMA Dermatology|March 5, 2025
Alopecia Areata-Specific Patient-Reported Outcome Measures: A Systematic ReviewEmadodin Darchini-Maragheh, Anthony Moussa, Nicole Yoong, et al.JAMA Dermatology|March 5, 2025
Effectiveness of Adalimumab Biosimilars and Originator for PsoriasisDuc Binh Phan, Anthony P Bewley, Philip Laws, et al.JAMA Dermatology|December 18, 2024
Interobserver and Intraobserver Agreement on the Treatment of Infantile HemangiomasMaría Colmenero-Sendra, Javier Del Boz-González, Mercè Grau-Pérez, et al.JAMA Dermatology|December 11, 2024
Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality ImprovementAndrew Alexis, Amy McMichael, Neelam Vashi, et al.JAMA Dermatology|November 27, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical TrialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.JAMA Dermatology|October 23, 2024
Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 WeeksAmy S Paller, Pedro Mendes-Bastos, Elaine Siegfried, et al.JAMA Dermatology|September 25, 2024
Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical TrialDaying Zhang, Tiechi Lei, Lanying Qin, et al.JAMA Dermatology|October 30, 2024
Psychometric Properties and Meaningful Change Thresholds of the Vitiligo Area Scoring IndexKhaled Ezzedine, Ahmed M Soliman, Heidi S Camp, et al.JAMA Dermatology|March 5, 2025
Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical TrialsNeal Bhatia, James Del Rosso, Linda Stein Gold, et al.JAMA Dermatology|February 26, 2025
Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With PsoriasisApril W Armstrong, Kathryn Lee, Danielle Yee, et al.Pageof 160